摘要
目的:观察国产吉西他滨联合5-氟尿嘧啶治疗晚期胰腺癌临床疗效及不良反应。方法:19例晚期胰腺癌患者随机分为两组,观察组10例,给予GCF方案(吉西他滨联合5-氟尿嘧啶),21天为1周期;对照组9例,给予FAM方案(5-氟尿嘧啶联合阿霉素、丝裂霉素),21天为1周期,均至少化疗2周期。结果:19例患者均可评价疗效和不良反应。临床受益反应率明显优于对照组(50%vs22%,P<0.05);观察组中位生存期和1年生存率也明显优于对照组(P<0.05);主要不良反应为白细胞下降、胃肠道反应,均较对照组轻,其它不良反应两组相似均可耐受。结论:吉西他滨联合5-氟尿嘧啶治疗晚期胰腺癌近期临床疗效较高,不良反应可以耐受。
Objective:To observe the effect of domestic gemcitabine and 5 -fluorouracil treatment for advanced pancreatic cancer. Methods:Nineteen patients with advanced pancreatic cancer patients were randomly divided into two groups, the observer group 10 cases treated with GCF programme (gemcitabine and 5 -fluorouracil), a cycle of 21 days for the control group nine cases, given FAM programme (5 -fluorouracil combined doxorubicin, silk out Adriamycin) ,for a period of 21 days,at least two cycles. Results:All 19 patients can be evaluated. Clinical benefit response rate was superior to the control group (50% vs 22% P 〈0.05) ;observer group in the median survival time and one - year survival rate was significantly better than the control group ( P 〈 0.05 ) ; major adverse reactions were leukopenia, stomach reaction,light than the control group, other adverse reactions can be tolerated. Conclusion:Gemcitabine and 5 - fluorouracil treatment for advanced pancreatic cancer is effective the recent high, adverse reactions can be tolerated.
出处
《现代肿瘤医学》
CAS
2009年第5期898-899,共2页
Journal of Modern Oncology
关键词
5-氟尿嘧啶
吉西他滨
联合化疗
晚期胰腺癌
5 - fluorouracil
gemcitabine
combined chemotherapy
advanced pancreatic cancer